Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, September 10, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, September 9, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Paul Matteis Upgraded (BMRN) to Strong Buy and Increased Target to $96 on, Sep 9th, 2021
Paul Matteis of Stifel, Upgraded "BioMarin Pharmaceutical Inc." (BMRN) to Strong Buy and Increased Target from $86 to $96 on, Sep 9th, 2021.
Paul has made no other calls on BMRN in the last 4 months.
There is 1 other peer that has a rating on BMRN. Out of the 1 peers that are also analyzing BMRN, all agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Kennen MacKay of "RBC Capital" Maintained at Hold with Increased Target to $88 on, Thursday, July 29th, 2021
